Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine

International Journal of Molecular Medicine

Volumn 3, Issue 6, 1999, Pages 647-653

  Yiwei, L I ^a   Singh, Brahmchetna ^a   Ali, Nasima ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Auristatin PE; Gemcitabinc; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; OLIGOPEPTIDE; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SOBLIDOTIN;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE; CELL DIVISION; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DEOXYCYTIDINE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033143029     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. American Cancer Society: Cancer facts and figures 1998. Am Cancer Society Inc, Atlanta, 1998.
2. Howe JR and Conlon KC: The molecular genetics of pancreatic cancer. Surg Oncol 6: 1-18, 1997.
3. Poncct J, Busquet M, Roux F, Pierre A, Atassi G and Jouin P: Synthesis and biological activity of chimcric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem 41: 1524-1530, 1998.
4. Pettit GR, Srirangam JK, Barkozy J, Williams MD, Durkin KPM, Boyd MR, Bai R, Hamel E, Schmidt JM and Chapuis JC: Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anticancer Drug Des 10: 529-544, 1995.
5. Dynlacht BD: Regulation of transcription by proteins that control the cell cycle. Nature 389: 149-152, 1997.
6. Csoka K, Liliemark J, Larsson R and Nygren P: Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematolpgical or solid tumors. Semin Oncol 22 (Suppl. 11): 47-53, 1995.
7. Huanc P and Plunkctt W: Induction of apoptosis by gemcitabine. Scmin Oncol 22 (Suppl. 11): 19-25, 1995.
8. Fountzilas G, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, Briassoulis E, Pavlidis P, Kosmidis P and Skarlos D: Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advance head and neck cancer. Semin Oncol 24 (Suppl. 19): S28-S32, 1997.
9. Moore MJ, Tannock IF, Ernst DS, Huan S and Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445, 1997.
10. Cortes-Funes H, Martin C, Abratt R and Lund B: Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs 8: 582-587, 1997.
11. Hui YF and Reitz J: Gemcitabine: a cytidine analogue active acainst solid tumors. Am J Health Syst Pharm 54: 162-170, 1997.
12. Noble S and Goa KL: Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54: 447-472, 1997.
13. Michael M and Moore M: Clinical experience with gemcitabine in pancreatic cancer. Oncology 11: 1615-1622, 1997.
14. Mohammad RM, Al-Katib A, Pettit GR, Vaitkcvicius VK, Majumdar APN and Sarkar FH: An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Clin Cancer Res 4: 887-894, 1998.
15. Mohammad RM, Dugan MC, Mohamed AN, Almatch VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK and Sarkar FH: Establishment of human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic asents. Pancreas 16: 19-25, 1998.
16. Sarkar FH, Joshi US, Adsay V and Mohammad RM: Experimental models of human pancreatic tumors for clinical therapy. In: Pancreatic Cancer: Advances in Molecular Pathology, Diagnosis and Clinical Management. Sarkar FH and Dugan MC (eds). Eaton Publishing, MA, pp165-188, 1998.
17. Plunkett W, Huang P, Xu Y-Z, Heinemann V, Gruncwald R and Gandhi V: Gemcitabine: metabolism mechanisms of action, and self-potcntiation. Semin Oncol 22 (Suppl. 11): 3-10, 1995.
18. Cronaucr MV, Klocker H, Talasz H, Geisen FH, Hobisch A, Radmayr C, Bock G, Culig Z, Schirmer M, Rcissigl A, Bartsch G and Konwalinka G: Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 28: 172-181, 1996.
19. Green MR: Gemcitabine: we've reached the end of the bcginning. Scmin Oncol 23 (Suppl. 10): 99-100, 1996.
20. Turner T, Jackson WH, Pettit GR, Wells A and Kraft AS: Treatment of human prostate cancer cells with dolastatin 10, a pcptidc isolated from a marine shell-less mollusc. Prostate 34: 175-181, 1998.
21. Maki A, Diwakaran H, Rcdman B, Al-Asfar S, Pettit GR, Mohammacl RM and AI-Katib A: The bcl-2 and p53 oncoprotcins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticanccr Drugs 6: 392-397, 1995.
22. Mani S and Ratain MJ: Promising new agents in oncologic treatment. Curr Opin Oncol 8: 525-534, 1996.
23. Schmitt E, Sane AT, Steyaert A, Cimoli G and Bertrand R: The Bcl-xL and Bax-alpha control point: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-scnsitivc protcasc and caspasc activation. Biochem Cell Biol 75: 301-314, 1997.
24. Salomons GS, Brady HJ, Verwijs-Janssen M, Van JD, Hart AA, Van H, Behrcn K and Smets LA: The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 71: 959-965, 1997.
25. Findley HW, Gu L, Ycagcr AM and Zhou M: Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89: 2986-2993, 1997.
26. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T and Brcdesen DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262: 1274-1277, 1993.
27. Vogelstein B and Kinzlcr KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
28. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, - Trent JM, Lin D, Mercer WE, Kinzler KW and Vogclstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
29. Harper JW, Adami GR, Wci N, Kcyomarsi K and Elledge SJ: The p21 Cdk-intcracting protein Cipl is a potent inhibitor of G1 cyclin-depcndcnt kinase. Cell 75: 805-816, 1993.
30. Agarwal ML, Agarwal A, Taylor WR and Stark GR: p53 controls both the G2/M and the G l cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sei USA 92: 8493-8497, 1995.
31. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinase. Nature 366:701-704. 1993.
32. Stcinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, et al: Induction of p21 (WAF-1/CIPl) during differentiation. Oncoacne 9: 3389-3396, 1994.
33. Datto MB, Li Y, Panus JF, Howc DJ, Xiong Y and Wang XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibition p21 throueh a p53-independcnt mechanism. Proc Natl Acad Sei USA 92: 5545-5549, 1995.
34. Kosaka C, Sasaguri T, Ishida A and Ogata J: Cell cycle arrest in the G2 phase induced by phorbol ester and diacylglycerol in vascular endothelial cells. Am J Physiol 270: C170-C178, 1996.
35. Zhu D, Dix DJ and Eddy EM: HSP70-2 is required for CDC2 kinase activity in meiosis 1 of mouse spermatocytcs. Development 124: 3007-3014, 1997.